The treatment of anti-mGluR5 encephalitis, akin to other autoimmune conditions of the central nervous system, should emphasize tailored therapeutic strategies, particularly in cases with atypical clinical manifestations or comorbidities involving other CNS autoantibody-mediated diseases. This evidence concerns the gene GRM5 and viral encephalitis.